The original goals of the project can be broken into three overarching categories:
Develop a multiplex panel of candidate sepsis biomarkers and assess their potential to differentiate sepsis from SIRS.
The original objective was to develop a panel of candidate biomarkers known to have links to sepsis. An initial panel of 12 markers was condensed to a high priority 6-plex which was run across patient samples. Results indicated increased levels of cytokines IL-6 and IL-8, and high levels of these markers in a statistically significant subset of SIRS samples raising interesting questions about the reliability of SIRS criteria in indicating patients most at risk of infection.
Advance and validate the performance/benefits of a novel multiplexing platform for biomarker screening.
This component of the project focused on the advanced development of the Bio-ID platform by Inanovate. Advances were made in the laser system and a valve-free’ fluidic cartridge system, resulting in a significant upgrade for the Bio-ID system and positions the system much more effectively as Inanovate builds towards commercial launch of the system with selected beta sites.
Pending positive biomarker validation, position both platform and biomarker panel for further trials to assess clinical utility and ready for commercial launch.
The work on the biomarkers did not deliver a conclusive set of markers to advance into further trials. However, sufficient progress was made to warrant further investigation into the 6-plex, and extend this multiplex into a large panel of candidate markers for continued screening. The consortium members intend to source further funding opportunities to continue building towards a clinically useful marker panel.